Hyperpolarizied 13C MRSI is a better predictor of survival than tumor size in treated glioblastoma

Resistance to current therapy and recurrence is not only common in glioblastoma but also expected. PI3K/Akt/mTOR signaling pathway, activated in most glioblastoma, represents an important target in alternative therapeutic approach. In order to prepare for an upcoming clinical trial, the goal of this study was to expand upon previous studies, and to confirm reproducibility in different model systems and genetic background, and with a novel PI3K/Akt/mTOR inhibitor. We used hyperpolarized 13C MRSI, and 1H MRS, and to monitor the effect of the dual PI3K/mTOR inhibitor XL765 (SAR245409) and TMZ alone or in combination in GS-2 tumors in mice.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.